6MY.F - Mylan N.V.

Frankfurt - Frankfurt Delayed Price. Currency in EUR
16.20
-0.50 (-2.99%)
As of 8:00AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close16.70
Open16.20
Bid16.20 x N/A
Ask16.80 x N/A
Day's Range16.20 - 16.20
52 Week Range15.00 - 34.40
Volume150
Avg. Volume760
Market Cap8.499B
Beta (3Y Monthly)1.29
PE Ratio (TTM)35.22
EPS (TTM)0.46
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Teva, 19 other drug companies accused of inflating drug prices
    Yahoo Finance Videolast month

    Teva, 19 other drug companies accused of inflating drug prices

    Pharmaceutical company Teva is accused of inflating drug prices. The stock plummeting after 44 states accused Teva and 19 other drug companies of driving up the market prices for generic drugs to avoid competition. Yahoo Finance's Seana Smith and Jared Blikre discuss.

  • Reuters20 days ago

    UPDATE 1-CtW opposes re-election of members of Mylan board's governance panel

    Union pension fund adviser CtW Investment Group on Friday urged Mylan NV shareholders to vote against the company's four director nominees, who are on the board's nominating and governance committee. In a letter to shareholders http://ctwinvestmentgroup.com/wp-content/uploads/2019/06/Mylan_Final_6_7_2019.pdf, CtW said that Mylan needs a clawback that includes recoupment of executive pay for misconduct related to supervisory failures and not just conduct that results in financial restatements.

  • Reuters20 days ago

    CtW urges Mylan shareholders to vote against board nominees for panel

    Union pension fund adviser CtW Investment Group on Friday urged Mylan NV shareholders to vote against the company's nominees for the board's nominating and governance committee. In a letter to shareholders http://ctwinvestmentgroup.com/wp-content/uploads/2019/06/Mylan_Final_6_7_2019.pdf, CtW said that Mylan needs a clawback that includes recoupment of executive pay for misconduct related to supervisory failures and not just conduct that results in financial restatements. CtW works with union pension funds affiliated with Change to Win and estimates that the funds with whom it works hold about 885,000 shares of Mylan.

  • How Much Could Generic Pharmas Have To Fork Over In Antitrust Lawsuit?
    Investor's Business Daily23 days ago

    How Much Could Generic Pharmas Have To Fork Over In Antitrust Lawsuit?

    Teva Pharmaceutical and Mylan could fork over $2.4 billion in damages, an analyst suggested after pharma company Heritage Pharmaceuticals admitted to fixing the prices of generic drugs.

  • Pharma Giant Crashes To 19-Year Low On Generic Drugs Lawsuit
    Investor's Business Dailylast month

    Pharma Giant Crashes To 19-Year Low On Generic Drugs Lawsuit

    Teva crashed to a 19-year low Tuesday as a lawsuit alleging a generic drugs pricing racket continued to hammer the pharmaceutical company. An analyst cut his price targets on Teva and Mylan.

  • An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars
    Investor's Business Dailylast month

    An Antitrust Lawsuit Could Cost Generic Pharmas Billions Of Dollars

    Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.

  • Reuterslast month

    South Africa's Aspen sells Australian prescription portfolio to Mylan

    Aspen Pharmacare said on Monday that Mylan NV had exercised an option to buy the South African drugmaker's portfolio of prescription and over-the-counter products in Australia for 188 million Australian dollars ($130 million). In December, Aspen said its wholly owned subsidiary incorporated in Mauritius, Aspen Global Incorporated, and its Australian subsidiaries had entered into a distribution arrangement with Alphapharm, a subsidiary of Mylan in respect of the portfolio commercialized in Australia and New Zealand. "The divestment is in line with the group's ongoing portfolio management approach and its stated intention to not only acquire value enhancing products, but to also divest of non-core assets, thereby ensuring enhanced operational focus," Aspen said in a statement.

  • Generic Drugs Are Stabilizing — Can They Survive An Antitrust Scandal?
    Investor's Business Dailylast month

    Generic Drugs Are Stabilizing — Can They Survive An Antitrust Scandal?

    The prices of generic drugs across the universe of pharmaceutical companies appeared to stabilize in the first quarter — shucking off years of broad decline, Wall Street analysts say.

  • Here's Why Generic-Drug Manufacturers Were Down Monday
    Motley Foollast month

    Here's Why Generic-Drug Manufacturers Were Down Monday

    Forty-four states have brought a lawsuit against the industry.

  • Mylan Reiterates 2019 Revenue Guidance for These Segments
    Market Realistlast month

    Mylan Reiterates 2019 Revenue Guidance for These Segments

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidance for Europe and Rest of World In the first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance in the mid-single

  • Barrons.comlast month

    The Dow Plunges 617 Points Because China Is Hitting Back With Retaliatory Tariffs

    News of China’s retaliatory tariffs sent shares tumbling. The Dow Jones Industrial Average lost 2.38% to close at 25,324.99. The S&P 500 has dropped 2.41% to finish at 2811.87, and the Nasdaq Composite dropped 3.41% to close at 7647.02.

  • Barrons.comlast month

    2 Drug Stocks to Buy as Health Care Suffers, According to JPMorgan

    Health-care stocks and drugmakers have suffered from pre-election worries, but JPMorgan says there are still some worth buying.

  • Mylan Reiterated 2019 Revenue Growth Guidance for North America
    Market Realistlast month

    Mylan Reiterated 2019 Revenue Growth Guidance for North America

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)North America revenue growth trendsDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed its YoY revenue growth rate guidance of high-single-digits for its

  • Stocks Dive As China Trade War Worsens; Teva, Mylan Tanks On Lawsuits
    Investor's Business Dailylast month

    Stocks Dive As China Trade War Worsens; Teva, Mylan Tanks On Lawsuits

    Apple dragged the Nasdaq and Dow Jones industrials lower Monday as a deepening China trade war spurred early selling and a tanker attack boosted oil prices.

  • A Look at Mylan’s Expense Guidance in Fiscal 2019
    Market Realistlast month

    A Look at Mylan’s Expense Guidance in Fiscal 2019

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Expense guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its guidance for fiscal 2019 SG&A (selling, general, and administrative) expenses to

  • What to Expect from Mylan’s Gross Margin and EBITDA
    Market Realistlast month

    What to Expect from Mylan’s Gross Margin and EBITDA

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Gross margin guidanceAt the Raymond James 40th Annual Institutional Investors Conference, Mylan (MYL) guided for an adjusted gross margin of 53.0% to 54.0% for fiscal 2019, a

  • Mylan Reiterated Fiscal 2019 Adjusted EPS Guidance
    Market Realist2 months ago

    Mylan Reiterated Fiscal 2019 Adjusted EPS Guidance

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Adjusted EPS guidanceDuring its first-quarter earnings conference call, Mylan (MYL) reaffirmed fiscal 2019 adjusted EPS guidance of $3.80 to $4.80, which would be a decline of

  • Mylan Reiterated Fiscal 2019 Revenue Guidance
    Market Realist2 months ago

    Mylan Reiterated Fiscal 2019 Revenue Guidance

    Is Mylan an Attractive Pick after Q1 Results?(Continued from Prior Part)Revenue guidanceIn the first-quarter earnings conference call, Mylan (MYL) reaffirmed its fiscal 2019 revenue guidance of $11.5 billion to $12.5 billion. The company expects to

  • What Are Analysts Recommending for Mylan after Q1 Results?
    Market Realist2 months ago

    What Are Analysts Recommending for Mylan after Q1 Results?

    Is Mylan an Attractive Pick after Q1 Results?Stock price movementsOn May 7, Mylan (MYL) reported first-quarter results. The company reported revenues of $2.50 billion, a YoY decline of 7% or around $200 million short of the consensus estimate.

  • Mylan Stock Jumps On Rumored Bid After Lackluster First Quarter
    Investor's Business Daily2 months ago

    Mylan Stock Jumps On Rumored Bid After Lackluster First Quarter

    Mylan stock jumped Thursday on a report the Carlyle Group could be prepping to bid on it following the pharmaceutical company's lackluster first-quarter sales report earlier this week.

  • CNBC2 months ago

    Here are the biggest analyst calls of the day: Pinterest, US Steel, Mylan & more

    Here are the biggest calls on Wall Street on Wednesday

  • Barrons.com2 months ago

    The Dow Slumped 473 Points Because No One Wins a Trade War

    Market weakness could help bring both sides back together, but if tensions corporate confidence and capital spending could take a hit.

  • Associated Press2 months ago

    AIG and SolarEdge rise while Mylan and Phibro fall

    Stocks that moved substantially or traded heavily on Tuesday: American International Group Inc., up $3.19 to $50.30 The insurer reported solid underwriting gains in the first quarter and profit beat Wall ...